An explosive study on add-on effects of ribavirin in sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapy.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Sep 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 24 Dec 2015 New trial record